Opinion|Videos|July 23, 2024
Empowering Patients: Key Considerations for BTK Inhibitor Adherence
A conversation on how to empower patients and the considerations for BTK inhibitor adherence.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What are the key considerations for educating and empowering patients about BTK inhibitors to support adherence for the course of long-term treatment?
Advertisement
Related to this article
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.
Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Across the US, Obesity Care Still Lacks an Owner
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
5